OncoCyte’s (OCX) “Equal Weight” Rating Reaffirmed at Stephens

OncoCyte (NASDAQ:OCX)‘s stock had its “equal weight” rating restated by stock analysts at Stephens in a report issued on Wednesday, Benzinga reports. They presently have a $4.00 target price on the stock. Stephens’ price objective indicates a potential upside of 54.44% from the company’s previous close.

Several other equities analysts have also recently commented on OCX. Benchmark restated a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a report on Monday. StockNews.com initiated coverage on shares of OncoCyte in a report on Friday, April 12th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.90.

OncoCyte Trading Down 5.8 %

NASDAQ OCX traded down $0.16 on Wednesday, hitting $2.59. 35,749 shares of the stock were exchanged, compared to its average volume of 48,396. OncoCyte has a 52-week low of $2.08 and a 52-week high of $6.80. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $3.06.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Andrew Arno bought 33,898 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, with a total value of $99,999.10. Following the transaction, the director now directly owns 69,054 shares in the company, valued at $203,709.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 2,457,288 shares of company stock valued at $7,176,400. Insiders own 1.94% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of OncoCyte by 3.2% during the 4th quarter. Vanguard Group Inc. now owns 247,873 shares of the company’s stock worth $620,000 after purchasing an additional 7,784 shares during the period. DCF Advisers LLC increased its holdings in shares of OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock worth $37,000 after purchasing an additional 13,000 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of OncoCyte during the 1st quarter worth about $25,000. Goldman Sachs Group Inc. increased its holdings in shares of OncoCyte by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock worth $686,000 after purchasing an additional 24,964 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in shares of OncoCyte during the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.